In pursuit of the optimal hemocompatible left ventricular assist device

Left ventricular assist device (LVAD) implantation is a firmly established treatment modality for advanced heart failure; however, major complications such as nonsurgical bleeding, driveline infections, pump thrombosis, and stroke limit wider application to patients with less severe heart failure. Of note, more than 60% of patients who receive a continuous flow LVAD experience such severe adverse events within the first year.1
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Editorial Commentary Source Type: research